ClinicalTrials.gg
CompletedNCT03455829Updated May 6, 2023Results posted

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

A Phase 1/2 interventional study of G1T38 and Osimertinib in Carcinoma, Non-Small-Cell Lung, Lung Cancer and Non-small Cell Lung Cancer, sponsored by G1 Therapeutics, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by G1 Therapeutics, Inc. (part of Pharmacosmos A/S) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 523 open to participants now, 895 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
1,997th of 3,000
30 · median 56
Started
2018
with 160 others
Phase 1/2
487 of 3,373
120 open now
Registered
1,997th of 3,373
by date

Among the 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,997th largest by enrollment of the 3,000 interventional ones that give a count, is one of 161 that started in 2018, is one of 487 in phase 1/2, and was the 1,997th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

523 of the 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

518 more — sign in →

All 523 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This was a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer.

The study was an open-label design, planned to consist of 2 parts: a safety, pharmacokinetic, and dose-finding portion (Part 1), and a randomized portion (Part 2). Both parts were to include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase began on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 144 patients were planned to be enrolled in the study.

Read the detailed description

Part 2, the Phase 2 part of the study, was not conducted due to changes in corporate strategy. There were no safety signals identified in Phase 1/Part 1 that would have precluded the conduct of Part 2. As a result, 30 out of the planned 144 patients were enrolled.

All tumor assessments were conducted by the Investigators or site radiologist. In order to reduce the burden to the patients, data of overall survival (OS) were no longer required (since 29 January 2020). No OS analysis was conducted for Part 1 due to limited data in Part 1.

PK data for Cohorts 4 (150 BID) and 5 (200 BID) were not analyzed as they were deemed unnecessary, as the PK data from Cohorts 1-3 were sufficient to achieve the secondary study objective of assessing the effect of osimertinib on PK parameters of G1T38.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Lung Cancer
  • Non-small Cell Lung Cancer

Keywords

  • Lung Cancer
  • Non-small Cell Lung Cancer
  • CDK 4/6 Inhibitor
  • EGFR-Positive
  • EGFR Mutation- Positive
  • T790M
  • EGFR Mutant
  • lerociclib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed EGFR mutation for non-small cell lung cancer associated with EGFR TKI sensitivity
  • For Part 2, EGFR T790M mutation-positive tumor status
  • (LVEF) ≥ institution's lower limit of the reference range
  • For Part 1, evaluable or as defined by , Version 1.1
  • For Part 2, measurable disease as defined by RECIST, Version 1.1
  • performance status 0 to 1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with EGFR TKI within 9 days of first study dose
  • For Part 1, prior treatment with more than 2 for advanced NSCLC
  • For Part 2, prior treatment with osimertinib or other T790M active EGFR TKI
  • For Part 2, prior chemotherapy for advanced NSCLC
  • Active uncontrolled/symptomatic , carcinomatous meningitis, or
  • drug within 3 months or 5 half-lives, whichever is longer, of first study dose
  • Concurrent radiotherapy, radiotherapy within 28 days of first study dose, previous radiotherapy to the target lesion sites, or prior radiotherapy to > 25% of bone marrow
  • Prior hematopoietic stem cell or bone marrow transplantation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1 G1T38 + Osimertinib

    Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).

    Drug: G1T38 · Drug: Osimertinib

  • Experimental
    Part 1: Cohort 2 G1T38 + Osimertinib

    Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).

    Drug: G1T38 · Drug: Osimertinib

  • Experimental
    Part 1: Cohort 3 G1T38 + Osimertinib

    Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).

    Drug: G1T38 · Drug: Osimertinib

  • Experimental
    Part 1: Cohort 4 G1T38 + Osimertinib

    Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).

    Drug: G1T38 · Drug: Osimertinib

  • Experimental
    Part 1: Cohort 5 G1T38 + Osimertinib

    Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).

    Drug: G1T38 · Drug: Osimertinib

Interventions

  • DrugG1T38

    CDK 4/6 inhibitor

    Also known as: Lerociclib

  • EGFR TKI; 80 mg

    Also known as: Tagrisso

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity

    The percentage of patients experiencing DLTs in Part 1 of the study in each cohort, including: * Grade 4 neutropenia * ≥ Grade 3 neutropenic infection/febrile neutropenia * Grade 4 thrombocytopenia * ≥ Grade 3 thrombocytopenia with bleeding * ≥ Grade 3 nonhematologic toxicity (additional criteria for nausea, vomiting, diarrhea, or fatigue: lasting \> 5 days with maximal medical management) * Liver function test abnormalities meeting Hy's Law criteria (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] ≥ 3 × upper limit of normal \[ULN\] and total bilirubin ≥ 2 × ULN).

    Time frame: Cycle 1 Day -16 to Cycle 1 Day 28

Secondary outcomes

  1. Progression Free Survival (PFS)

    Median time (months) and 95% CI from date of first dose of study drug/randomization until date of documented disease progression or death due to any cause. Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines for tumor assessments were used to determine progression. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: 36 months

  2. Best Overall Tumor Response

    The percentage of patients who fall into each category of Best overall response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. When no imaging/measurement is done, the patient is not evaluable (NE); and if only a subset of lesion measurements are made, usually the case is also considered NE.

    Time frame: 21 months

  3. Pharmacokinetics of G1T38 and Metabolite G1T30: Maximum Plasma Concentration (Cmax)

    The observed peak plasma concentration determined from the plasma concentration versus time data.

    Time frame: Part 1, Cycle 1 Day -16 to Day -2.

  4. Pharmacokinetics of G1T38 and Metabolite G1T30: Area Under Curve - Plasma Concentration (AUC) Infinity

    Area under the concentration-time curve from time zero extrapolated to infinity using the linear-up log-down trapezoidal rule.

    Time frame: Part 1, Cycle 1 Day -16 to Day -2.

  5. Pharmacokinetics of G1T38 and Metabolite G1T30: Plasma: Terminal Half Life (T1/2)

    Terminal half-life, defined as 0.693 divided by the terminal phase rate constant by λz , determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.

    Time frame: Part 1, Cycle 1 Day -16 to Day -2.

  6. Pharmacokinetics of G1T38: Plasma - Volume of Distribution

    Volume of distribution in the terminal elimination phase, calculated as: Vz/F = (CL/F)/λz

    Time frame: Part 1, Cycle 1 Day -16 to Day -2.

07

Results

Posted May 1, 2023
Limitations and caveats
A limitation of the trial is small numbers of subjects, since only the Phase 1/Part 1 part of the trial was conducted. A lack of a control group, blinding and randomization also limits the utility of the information, so it is difficult to determine if there is any change in safety or tolerability of the combination of G1T38 + osimertinib from that of osimertinib alone or if there was any selection bias introduced.

Participant flow

Participant flow — Overall Study
MilestonePart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BID
Started76476
Completed00000
Not completed76476
Withdrew: Death23242
Withdrew: Study terminated and patients did not have progressive disease or died53223
Withdrew: Disease progression00011

Outcome measures

PrimaryDose Limiting Toxicity

The percentage of patients experiencing DLTs in Part 1 of the study in each cohort, including: * Grade 4 neutropenia * ≥ Grade 3 neutropenic infection/febrile neutropenia * Grade 4 thrombocytopenia * ≥ Grade 3 thrombocytopenia with bleeding * ≥ Grade 3 nonhematologic toxicity (additional criteria for nausea, vomiting, diarrhea, or fatigue: lasting \> 5 days with maximal medical management) * Liver function test abnormalities meeting Hy's Law criteria (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] ≥ 3 × upper limit of normal \[ULN\] and total bilirubin ≥ 2 × ULN).

Time frame:
Cycle 1 Day -16 to Cycle 1 Day 28
Reported as:
Count of participants · Participants
Dose Limiting Toxicity
ParticipantsPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BID
Dose Limiting Toxicity00100
SecondaryProgression Free Survival (PFS)

Median time (months) and 95% CI from date of first dose of study drug/randomization until date of documented disease progression or death due to any cause. Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines for tumor assessments were used to determine progression. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
36 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BID
Progression Free Survival (PFS)19.3 (2.0 to NA)6.0 (1.8 to NA)1.4 (0.7 to NA)7.2 (1.6 to NA)12.9 (3.6 to NA)
SecondaryBest Overall Tumor Response

The percentage of patients who fall into each category of Best overall response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. When no imaging/measurement is done, the patient is not evaluable (NE); and if only a subset of lesion measurements are made, usually the case is also considered NE.

Time frame:
21 months
Reported as:
Count of participants · Participants
Best Overall Tumor Response
ParticipantsPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BID
Complete Response (CR)00000
Partial Response (PR)21013
Stable Disease (SD)24130
Progressive Disease (PD)11321
Not Evaluable (NE)10011
SecondaryPharmacokinetics of G1T38 and Metabolite G1T30: Maximum Plasma Concentration (Cmax)

The observed peak plasma concentration determined from the plasma concentration versus time data.

Time frame:
Part 1, Cycle 1 Day -16 to Day -2.
Reported as:
Mean · ng/mL
Pharmacokinetics of G1T38 and Metabolite G1T30: Maximum Plasma Concentration (Cmax)
ng/mLPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QD
G1T38 Cycle 1 Day -1627.229 ± 8.93633.375 ± 12.21243.850 ± 21.942
G1T38 Cycle 1 Day -217.257 ± 1.47126.400 ± 2.68942.700 ± 25.107
Metabolite G1T30 Cycle 1 Day -163.080 ± 1.3013.568 ± 0.6334.220 ± 1.717
Metabolite G1T30 Cycle 1 Day -22.736 ± 0.7643.853 ± 1.1465.970 ± 4.369
SecondaryPharmacokinetics of G1T38 and Metabolite G1T30: Area Under Curve - Plasma Concentration (AUC) Infinity

Area under the concentration-time curve from time zero extrapolated to infinity using the linear-up log-down trapezoidal rule.

Time frame:
Part 1, Cycle 1 Day -16 to Day -2.
Reported as:
Mean · h*ng/mL
Pharmacokinetics of G1T38 and Metabolite G1T30: Area Under Curve - Plasma Concentration (AUC) Infinity
h*ng/mLPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QD
G1T38 Cycle 1 Day -16319.6 ± 107391.0 ± 85.6715.6 ± 359
G1T38 Cycle 1 Day -2277.4 ± 63.2390.0 ± 91.0802.3 ± 519
Metabolite G1T30 Cycle 1 Day -1628.443 ± 17.17530.853 ± 10.57753.971 ± 23.638
Metabolite G1T30 Cycle 1 Day -230.110 ± 11.25544.745 ± 13.92980.145 ± 66.239
SecondaryPharmacokinetics of G1T38 and Metabolite G1T30: Plasma: Terminal Half Life (T1/2)

Terminal half-life, defined as 0.693 divided by the terminal phase rate constant by λz , determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.

Time frame:
Part 1, Cycle 1 Day -16 to Day -2.
Reported as:
Mean · hour
Pharmacokinetics of G1T38 and Metabolite G1T30: Plasma: Terminal Half Life (T1/2)
hourPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QD
G1T38 Cycle 1 Day -1613.83 ± 1.9516.30 ± 4.3615.59 ± 2.12
G1T38 Cycle 1 Day -213.59 ± 2.8812.61 ± 1.7113.93 ± 2.14
Metabolite G1T30 Cycle 1 Day -1611.771 ± 7.24812.238 ± 8.07222.614 ± 3.297
Metabolite G1T30 Cycle 1 Day -213.722 ± 8.02518.220 ± 2.02718.582 ± 2.977
SecondaryPharmacokinetics of G1T38: Plasma - Volume of Distribution

Volume of distribution in the terminal elimination phase, calculated as: Vz/F = (CL/F)/λz

Time frame:
Part 1, Cycle 1 Day -16 to Day -2.
Reported as:
Mean · Liter
Pharmacokinetics of G1T38: Plasma - Volume of Distribution
LiterPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QD
G1T38 Cycle 1 Day -1614000 ± 654018700 ± 691015900 ± 9210
G1T38 Cycle 1 Day -214900 ± 466014800 ± 506012900 ± 6490

Adverse events

Collected over The SAE reporting period started at the time of informed consent and the AE reporting period started from the time of first dose of study drug; both were assessed through 30 calendar days after the last administration of lerociclib/osimertnib, an average of 11 months for each participant (Mean exposure + 30 days/1 month).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohort 1 Lerociclib at 200 mg QD2/7 (28.6%)2/7 (28.6%)7/7 (100%)
Part 1: Cohort 2 Lerociclib at 300 mg QD3/6 (50%)1/6 (16.7%)6/6 (100%)
Part 1: Cohort 3 Lerociclib at 400 mg QD2/4 (50%)1/4 (25%)4/4 (100%)
Part 1: Cohort 4 Lerociclib at 150 mg BID4/7 (57.1%)0/7 (0%)7/7 (100%)
Part 1: Cohort 5 Lerociclib at 200 mg BID2/6 (33.3%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BID
PneumothoraxRespiratory, thoracic and mediastinal disorders0/70/61/40/70/6
SepsisInfections and infestations0/70/60/40/71/6
Ischaemic strokeNervous system disorders0/71/60/40/70/6
PneumonitisRespiratory, thoracic and mediastinal disorders0/70/60/40/71/6
COVID-19 pneumoniaInfections and infestations1/70/60/40/70/6
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/70/60/40/70/6
Most frequent other events
Showing 10 of 138
Most frequent other events
EventPart 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BID
DiarrhoeaGastrointestinal disorders5/76/64/46/76/6
NauseaGastrointestinal disorders5/75/63/42/73/6
AnaemiaBlood and lymphatic system disorders5/72/62/41/70/6
VomitingGastrointestinal disorders5/74/62/41/72/6
Neutrophil count decreasedInvestigations5/71/62/42/70/6
HeadacheNervous system disorders5/71/61/42/71/6
LeukopeniaBlood and lymphatic system disorders4/72/61/41/70/6
NeutropeniaBlood and lymphatic system disorders4/73/61/42/70/6
Transaminases increasedInvestigations4/70/60/40/70/6
HyperglycaemiaMetabolism and nutrition disorders4/71/60/41/70/6

Baseline characteristics

All enrolled patients who were administered at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BIDTotal
Mean62.71 ± 11.26562.67 ± 8.77962.75 ± 7.80561.43 ± 15.75766.17 ± 3.76463.10 ± 10.118
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BIDTotal
Female6335421
Male131229
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BIDTotal
Hispanic or Latino300104
Not Hispanic or Latino3635623
Unknown or Not Reported101103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Cohort 1 Lerociclib at 200 mg QDPart 1: Cohort 2 Lerociclib at 300 mg QDPart 1: Cohort 3 Lerociclib at 400 mg QDPart 1: Cohort 4 Lerociclib at 150 mg BIDPart 1: Cohort 5 Lerociclib at 200 mg BIDTotal
American Indian or Alaska Native000000
Asian111014
Native Hawaiian or Other Pacific Islander000000
Black or African American000213
White1523415
More than one race000000
Unknown or Not Reported501208
08

Study locations

8 sites
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • UCLA Medical Center, Division of Hematology/Oncology/Clinical Research Unit
    Santa Monica, California 90404, United States
  • St Joseph Heritage Healthcare
    Santa Rosa, California 95403, United States
  • Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine Fox Building, Suite 200 G
    Miami, Florida 33136, United States
  • Mofitt Cancer Center
    Tampa, Florida 33612, United States
  • Univ. of Michigan Hospitals
    Ann Arbor, Michigan 48109, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22301, United States
  • Froedtert Hospital & the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Dec 2021, 44 months.

Results were first posted in May 2023, 1 year 4 months after primary completion.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 44 months is below that.

Counting every sponsor, half of 435 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2018
First posted
Mar 7, 2018
StartActual
Mar 29, 2018
Primary completionActual
Dec 14, 2021
CompletionActual
Feb 14, 2022
Results first posted
May 1, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03455829
Responsible party
Sponsor
First posted
Mar 7, 2018
Start date
Mar 29, 2018
Primary completion
Dec 14, 2021
Completion
Feb 14, 2022
Results posted
May 1, 2023
Last update
May 6, 2023

Study contacts

Clinical Contact
study director · G1 Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lerociclib

Start the discussion